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Abstract In mesangial cells angiotensin II (Ang II) has been
shown to activate extracellular regulated kinases 1 and 2 (ERK1/
2). Here, we studied the role of the epidermal growth factor
receptor (EGFR) and platelet-derived growth factor receptor
(PDGFR) in Ang II-induced ERK1/2 activation in human
mesangial cells. Ang II induced activation of ERK1/2 via the
AT1 receptor, and this response was blocked by the PDGFR-
selective tyrosine kinase inhibitor AG1295, but not by AG1478,
an EGFR-selective tyrosine kinase inhibitor, indicating partici-
pation of the PDGFR, but not of the EGFR in Ang II-induced
ERK1/2 activation. In agreement with this assumption, Ang II
caused tyrosine phosphorylation of the PDGFR and the adapter
protein Shc in an AG1295-sensitive fashion. In conclusion, our
data show that Ang II-induced activation of mitogenic signalling
cascade in human mesangial cells involves ligand-independent
activation of the PDGFR, but not of the coexpressed EGFR.
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1. Introduction
Mesangial cells are mesenchymal derived specialized peri-
cytes, that possess contractile ¢bers and exhibit smooth
muscle cell-like properties [1]. In renal disease mesangial cells
may proliferate and are subjected towards locally produced
vasoactive and proliferative peptides such as angiotensin II
(Ang II). Mesangial cell proliferation is regulated mainly by
receptor tyrosine kinase such as receptors for the epidermal
growth factor (EGF) and platelet-derived growth factor
(PDGF) and by G-protein-coupled receptors (GPCR) for vas-
oactive peptides such as Ang II and endothelins [2]. Two dis-
tinct subtypes of Ang II receptors (AT1, AT2) have been
characterized [3]. In mesangial cells the AT1 receptor with
its subtypes AT1A and AT1B predominates [4]. In rat mesan-
gial cells activation of AT1 receptor is coupled to ERK acti-
vation [5]. Activation of extracellular regulated protein kinase
(ERK) pathway has been considered to play a key role in
mitogenesis and hypertrophy of cells and acts as a conver-
gence point of receptor tyrosine kinase and GPCR activation
[6].
The mechanism of receptor tyrosine kinase-stimulated ERK
activation is well understood [7]. In contrast, heterogeneity
exists in the mechanism of MAPK activation by GPCRs.
Depending upon receptor and cell type, MAPK activation
may be mediated by G-protein K or LQ subunits, protein ki-
nase C-, Src-, phosphatidylinositol 3-kinase-, and Ras-depen-
dent or -independent pathways [8^10]. Ang II-induced signal-
ing towards ERK activation is not entirely clear and appears
to be cell type speci¢c. In fact, recent work suggests that Ang
II-induced ERK activation requires complex formation be-
tween Shc, Grb2, and Sos and subsequent activation of Ras
as well as several candidate tyrosine kinases such as proline-
rich tyrosine kinase (PYK2) [11], PDGFR-L [12], EGFR
[13,14], and Src family tyrosine kinases [15,16]. Moreover,
Ang II has been described to activate ERK either by a
PKC-dependent, Ras-independent pathway, or by a Ras-
and Src-dependent pathway after down-modulation of PKC
by phorbol ester [17]. In this report we demonstrate that in
human mesangial cells which express both the EGFR and the
PDGFR, AT1 receptor-induced ERK activation requires
PDGFR tyrosine kinase, and that Ang II does not utilize
the EGFR for ERK activation even when the PDGFR was
blocked.
2. Materials and methods
2.1. Materials
Ang II, PDGF-BB, human recombinant EGF, PD12319 and agar-
ose-conjugated anti-phosphotyrosine antibody were from Sigma (St.
Louis, MO, USA). Enhanced chemiluminescence (ECL) reagents, X-
ray ¢lms and horseradish peroxidase (HRP)-conjugated IgGs were
obtained from Amersham (Little Chalfont, UK). Anti-ERK2 anti-
body, AG1478 [18], AG1295 [19] and PP1 were from Calbiochem
(La Jolla, CA, USA). The antibody raised against dually phosphory-
lated activated ERK1/2 and the ERK1/2 assay kit were from New
England Biolabs (Beverly, MA, USA). Anti-PDGFR antibody was
from Upstate Biochech Inc. (Lake placid, NY, USA). Antibodies
against Shc, Grb2, and the HRP-labelled anti-phosphotyrosine anti-
body were from Transduction Laboratories (San Diego, CA, USA).
RPMI 1640 medium and fetal calf serum (FCS) were from Gibco
(Eggenstein, Germany). Polyvinylidene di£uoride transfer membranes
were from Millipore (Eschborn, Germany). Losartan was from MSD
(Mu«nchen, Germany).
2.2. Cell culture
Human mesangial cells were isolated by sequential sieving tech-
nique as described from patients undergoing tumor nephrectomy
[20]. All experiments were performed from passages 3^6. Mesangial
cell cultures were identi¢ed by morphological and immunological
characteristics such as positive staining for actin and negative staining
for Factor VIII and cytokeratin. To exclude ¢broblast contamination
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cells were grown for 2 weeks in L-valine-de¢cient RPMI 1640 supple-
mented with 10% FCS, 10 mM HEPES, pH 7.4, 1 mM sodium pyr-
uvate, 100 U/ml penicillin/streptomycin. Culture media were replaced
three times per week.
2.3. Cell stimulation and preparation of cell extract
Cells were grown until subcon£uence in media supplemented with
10% FCS. Cells were washed once and made quiescent by a 48 h
preincubation in serum-free medium. After stimulation, incubations
were terminated by washing cells twice with ice-cold phosphate-bu¡-
ered saline (PBS). After scraping the cells were pelleted by centrifu-
gation and lysed in a bu¡er containing 1% Triton X-100, 5 mM
EDTA, 10 mM Tris^HCl, pH 8.0, 1.0 mM PMSF, 2 mM dithiothrei-
tol, 10 mM sodium pyrophosphate, 0.2 mM sodium orthovanadate.
2.4. Immunoprecipitation of the PDGFR and tyrosine-phosphorylated
proteins
The PDGFR types K and L or tyrosine-phosphorylated proteins
were immunoprecipitated with anti-PDGFR antibody recognizing K
and L isoforms and protein G-Sepharose or agarose-conjugated anti-
phosphotyrosine antibody by incubation at 4‡C overnight with gentle
agitation. Immunoprecipitates were washed twice in lysis bu¡er, re-
suspended in SDS^PAGE sample bu¡er, and boiled for 5 min. Fol-
lowing SDS^PAGE, proteins were transferred to polyvinylidene di-
£uoride membranes and processed for immunoblot analysis.
2.5. Immunoblotting
Western blotting was carried out as described recently [21]. Non-
speci¢c binding sites were blocked in PBS containing 0.1% Tween 20
(PBST) and 3% bovine serum albumin or PBST containing 5% skim
milk. Thereafter, the immunoblots were washed to remove excess
primary antibody and incubated with appropriate HRP-conjugated
secondary antibodies. Antigen^antibody complexes were visualized
using the ECL system. In some experiments ¢lters were reprobed after
stripping in a solution containing 0.1 M Tris^HCl, pH 8.2, 2% SDS
and 0.1 M L-mercaptoethanol for 30 min at 52‡C.
2.6. ERK1/2 activity assay
To determine ERK1/2 activity we used a commercially available
assay kit (New England Biolabs, Beverly, MA, USA). In brief, active
phosphorylated ERK1/2 was immunoprecipitated from cell lysates.
The immunoprecipitates were incubated in the presence of Elk-1
and ATP in kinase bu¡er provided by the manufacturer. Phosphory-
lated Elk-1 was detected by Western blotting using a phospho-Elk-1-
(Ser-383) speci¢c antibody and chemiluminescent detection with an
HRP-conjugated secondary antibody.
2.7. Data presentation
All experiments were performed at least three times with a similar
result and representative immunoblots are shown.
3. Results and discussion
In renal disease mesangial cells may proliferate and are
subjected towards locally produced vasoactive peptides such
as angiotensin II. The MAPK pathway has been considered to
play a pivotal role in mitogenesis and hypertrophy of cells and
acts as a convergence point in G-protein-coupled receptor
activation and growth hormone receptor activation. Recently,
it has been shown that Ang II activates ERK1/2 via activation
of the AT1 receptor in rat mesangial cells [5]. We con¢rmed
these results in human mesangial cells by speci¢c detection of
the dually phosphorylated, activated form of ERK1/2 by
Western blotting. Ang II (1 WM) stimulated phosphorylation
of ERK1 and ERK2. The AT1 receptor blocker Losartan (1
WM) completely inhibited Ang II-induced ERK1/2 phosphor-
ylation, whereas the AT2 receptor blocker PD123319 (1 WM)
had no e¡ect (data not shown).
The convergence of GPCR and RTK signaling pathways is
reported for PDGF [11], EGF [13,22] and IGF [23] receptors.
To investigate possible involvement of the EGFR or the
PDGFR in Ang II-induced ERK activation in human mesan-
gial cells, growth-arrested cells were stimulated with Ang II,
PDGF (100 ng/ml), or EGF (100 ng/ml) alone or in combi-
nation with the PDGFR-speci¢c tyrosine kinase inhibitor
AG1295 (5 WM) or the EGFR-speci¢c tyrosine kinase inhib-
itor AG1478 (0.5 WM). As shown in Fig. 1A, AG1295 abol-
ished both PDGF- and Ang II-induced phosphorylation of
ERK1/2. In contrast, the EGFR-speci¢c tyrosine kinase in-
hibitor AG1478 had no e¡ect, indicating that the PDGFR,
but not the EGFR, is involved in Ang II-induced MAPK
phosphorylation. Similarly, when ERK1/2 activity was as-
sayed by detection of Elk-1 phosphorylation as substrate for
ERK1 and ERK2, AG1295 inhibited both Ang II- and
PDGF-induced ERK1/2 activation (Fig. 1B). To investigate
if Ang II stimulates tyrosine phosphorylation of the EGFR or
PDGFR, serum-starved cells were incubated with Ang II for
the indicated time and subjected to immunoprecipitation with
agarose-conjugated anti-phosphotyrosine antibodies. Immu-
noprecipitates were analyzed by anti-EGFR and anti-PDGFR
Western blotting. As shown in Fig. 2A, Ang II caused tyro-
sine phosphorylation of the PDGFR, whereas Ang II did not
alter EGFR tyrosine phosphorylation. A similar result was
obtained when cells were stimulated with Ang II, and the
PDGFR was immunoprecipitated and the immunoprecipitates
were analyzed by anti-phosphotyrosine Western blotting (Fig.
2B). AG1295 abolished Ang II-induced tyrosine phosphory-
lation of the PDGFR. Downstream signaling of both the
PDGFR and the EGFR has been reported to involve recruit-
ment of both Shc and Grb2 to the receptors. Immunopreci-
pitation of cell lysates from Ang II- or PDGF-stimulated cells
with anti-phosphotyrosine antibody and analysis of the immu-
noprecipitates by anti-Shc Western blotting revealed that Ang
II caused tyrosine phosphorylation of Shc isoforms, although
Fig. 1. E¡ect of Ang II, PDGF and EGF alone and in combination
with the PDGFR AG1295 or EGFR AG1478 speci¢c tyrosine ki-
nase inhibitors on phosphorylation (A) and activity (B) of ERK1/2
in human mesangial cells. Cells were incubated with Ang II (1 WM),
PDGF (100 ng/ml) or EGF (100 ng/ml) with and without AG1295
(5 WM) or AG1478 (0.5 WM) for 10 min. A: After lysis of the cells
equal amounts of protein were immunoblotted with an anti-phos-
pho-ERK1/2 antibody (upper part). The blot was stripped and re-
probed with anti-ERK2 antibody (lower part). B: Activity was
measured by immunoprecipitation of activated ERK1/2 and in vitro
phosphorylation of the ERK1/2 substrate Elk-1.
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to a smaller extent than PDGF. AG1295, but not AG1478
blocked Ang II-induced tyrosine phosphorylation of Shc, in-
dicating that Ang II-induced tyrosine phosphorylation of Shc
is mediated by the PDGFR, but not by the EGFR (Fig. 3A).
Accordingly, Ang II increased the amount of Shc binding to
exogenous Grb2 (Fig. 3B). However, we did not ¢nd signi¢-
cant di¡erences in the amounts of Shc and Grb2 in PDGFR
immunoprecipitates from Ang II-stimulated cells, whereas
PDGF clearly induced these responses (Fig. 3C). Precedent
for this phenomenon comes from vascular smooth muscle
cells, in which stretch-stress leads to tyrosine phosphorylation
of the PDGFR without signi¢cant increase in the amount of
Grb2 coprecipitating with the PDGFR [24]. Thus, one can
speculate that an increased complex formation of the PDGFR
with Shc and Grb2 is not necessary for activation of the ERK
pathway by Ang II. Another possibility is that the recruitment
of other adapter proteins such as Gab1 or Cbl [25^28] are
involved in Ras and ERK activation by Ang II in mesangial
cells. AT1 receptor-induced ERK activation has been exten-
sively studied in vascular smooth muscle cells. In these cells
Ang II has been reported to induce tyrosine phosphorylation
of the PDGFR [12]. A more recent study indicates that Ang II
induces tyrosine phosphorylation of the EGFR and Shc, com-
plex formation of Shc, Src, and Grb2 with the EGFR, and
that AG1478, but not AG1295, inhibited Ang II-induced
ERK activation [13], suggesting that tyrosine phosphorylation
of the PDGFR is not involved in ERK activation in vascular
smooth muscle cells. It has recently been reported that Src
mediates lysophosphatidic acid-induced EGFR tyrosine phos-
phorylation [9], whereas in another study PP1, an Src family
tyrosine kinase inhibitor [29], had no e¡ect [30]. To examine if
Src family tyrosine kinase is involved in Ang II-induced tyro-
sine phosphorylation of the PDGFR, cells were stimulated in
the absence or presence of PP1. As shown in Fig. 3D, PP1
(10 WM) did not inhibit Ang II-induced PDGFR tyrosine
phosphorylation, suggesting that Src family tyrosine kinases
are not involved in this process in mesangial cells. In cardiac
Fig. 2. E¡ect of Ang II on PDGFR and EGFR tyrosine phosphory-
lation. A: Quiescent mesangial cells were stimulated with Ang II (1
WM) or EGF (100 ng/ml) for the indicated time. Anti-phosphotyro-
sine immunoprecipitates were analyzed by anti-PDGFR and anti-
EGFR Western blotting. B: Serum-deprived cells were stimulated
with Ang II (500 nM) or PDGF (100 ng/ml) alone or in the pres-
ence of AG1295 (5 WM). Anti-PDGFR immunoprecipitates were an-
alyzed by anti-phosphotyrosine and anti-PDGFR Western blotting.
Fig. 3. E¡ect of Ang II and PDGF on tyrosine phosphorylation of Shc. Serum-deprived mesangial cells were stimulated with Ang II (500 nM)
or PDGF (100 ng/ml) in the presence or absence of AG1295/AG1478 or PP1 (10 WM) for the indicated time. In A, lysates were immunopreci-
pitated with anti-phosphotyrosine antibody followed by anti-Shc Western blotting. B: Lysates were incubated with Grb2 agarose followed by
anti-Shc Western blotting. C: Lysates were immunoprecipitated with anti-PDGFR antibody followed by anti-PDGFR, anti-Shc and anti-Grb2
Western blotting. D: Lysates were immunoprecipitated with anti-phosphotyrosine antibody followed by anti-PDGFR Western blotting.
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myocytes [14] and GN4 rat liver epithelial cells Ang II stim-
ulates EGFR activation [17]. Similar to the present study
showing that the AT1 receptor, a Gq-coupled receptor [4],
stimulates ERKs by a PDGFR-dependent mechanism.
Recent studies have shown that the receptor for lysophos-
phatidic acid, a Gi-coupled receptor, induces ERK activation
through a PDGFR-dependent mechanism [31,32]. Thus, it is
reasonable to assume that GPCR can utilize both the EGFR
and the PDGFR for activation of ERK depending on the cell
type investigated. A recent investigation showed that EGFR
transactivation by GPCR requires cleavage of pro-heparin-
binding EGF by a metalloproteinase [33]. Whether a similar
mechanism is involved in PDGF receptor transactivation re-
quires further investigation. Although numerous studies have
shown that AG1478 and AG1295 are highly speci¢c for inhi-
bition of the EGFR and the PDGFR tyrosine kinase, respec-
tively [13,22,34], we cannot exclude that it a¡ects other ki-
nases or signaling intermediates non-speci¢cally. However,
our data indicate that the e¡ects of AG1295 and AG1478
are speci¢c in our cells, since AG1295 did not a¡ect EGF-
induced EGFR autophosphorylation, tyrosine phosphory-
lation of Shc and ERK1/2 activation, whereas AG1478 com-
pletely inhibited EGFR autophosphorylation without inhibit-
ing PDGF- or Ang II-induced signaling.
In conclusion, the present study using human mesangial
cells shows that Ang II utilizes only the PDGFR to induce
tyrosine phosphorylation of Shc and to stimulate ERK1/2,
although these cells express both the PDGFR and the
EGFR. It remains to be determined why GPCR utilizes either
the PDGFR or the EGFR for activation of the ERK path-
way.
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